This is a non-interventional, prospective, single-arm, observational study describing the real-world effectiveness, safety, and PRO and HCRU data of ribociclib combined with adjuvant ET under conditions of routine clinical practice in HR+/HER2- EBC in premenopausal, perimenopausal and postmenopausal women, or men in Saudi Arabia.
Signed and dated Patient Informed Consent Form (PICF) obtained.
The patient is ≥ 18 years-old at the time of PICF signature.
Male or female patients with estrogen-receptor-positive and/or progesterone-receptor-positive BC.
Male or female patients with HER2- BC.
Ribociclib-based treatment regimen beyond adjuvant therapy for EBC.
Patients are currently participating in any other clinical trials.
Patients who previously received any other CDK4/6 inhibitor.
Patients who refused to sign informed consent.